Medical Cannabis Import Flow Experiences Delays in Brazil
Companies report delays in shipments clearance, while official data from Anvisa indicate reduced average deadlines and a high approval rate
The import process of medical cannabis-based products is facing a period of instability in Brazil, according to reports from sector companies. The main complaint involves prolonged delays, shipment retentions, and operational bottlenecks at the National Health Surveillance Agency (Anvisa), which have directly impacted access to prescribed treatments.
According to gathered information, over 300 shipments are reportedly stalled at Anvisa without analysis or progress. In another case, nearly 600 approved orders have not been forwarded to the Federal Revenue Service for customs clearance, a necessary step for product release. There are also reports of shipments that left the United States in early December 2025 and, by January 12, 2026, had not been delivered.
One of the reasons cited for the retentions is the requirement to prove the link between the import authorization and the person who signed the declaration, even when the patient themselves requests the authorization. According to reports, at least 41 orders have been held based on this interpretation, despite having a medical prescription and valid authorization.
In response, Anvisa states that the alleged delay is unfounded and that, in similar situations, issues usually stem from importer or courier failures. The agency also mentioned that, if specific cases are presented, it can inspect samples to identify whether delays are due to internal backlog or factors beyond its competence.
Anvisa emphasizes that the exceptional import of cannabis-derived products is regulated by RDC 660/2022, which allows individuals to import medications for personal and therapeutic use, with a medical prescription and authorization issued via Portal Gov.br. The regulation stipulates that the product is for personal and non-transferable use.
According to official data, between October 1 and December 31, 2025, 32,888 import petitions were filed by individuals, with an approval rate of 92%. The agency states that processes are typically analyzed within 72 hours after filing, and any systemic failures resulted in additional delays of only two to three days.